|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,866,866
What is the scope and primary claims of Patent 6,866,866?
U.S. Patent 6,866,866, granted on Mar. 15, 2005, to Eli Lilly and Company, covers methods for treating hyperuricemia and gout using a specific class of xanthine oxidase inhibitors. The patent claims include composition and method claims related to the use of certain 4-aminopyrazolopyrimidine derivatives.
Key claims:
-
Method claims: Administering a therapeutically effective amount of compounds with the structure represented as a 4-aminopyrazolopyrimidine derivative to treat hyperuricemia, gout, or related conditions.
-
Compound claims: The patent explicitly claims compounds within a defined chemical genus, emphasizing particular substituents on the core structure that confer xanthine oxidase inhibitory activity.
-
Formulation claims: Claims extend to pharmaceutical compositions comprising the claimed compounds, including dosage forms suitable for oral administration.
Chemical scope:
The patent covers a broad class of 4-aminopyrazolopyrimidine derivatives, with various substitutions at key positions, notably at the 2- and 4-positions. The claims specify both individual compounds and classes of compounds with certain substituents, such as alkyl, alkoxy, or halogen groups.
Limitations:
The claims are limited to compounds with specific substitution patterns and their use in treating diseases characterized by elevated uric acid levels. The scope excludes compounds outside the defined chemical genus and uses not related to hyperuricemia or gout.
How does Patent 6,866,866 fit within the patent landscape?
Prior art landscape (before 2005):
- Allopurinol: Existing since the 1960s as a xanthine oxidase inhibitor.
- Febuxostat: Approved in 2009, with prior patent filings dating mid-2000s, claiming non-purine inhibitors.
- Other compounds: Various non-purine inhibitors, including triazolopyrimidines, were known.
Patent family and related filings:
- Eli Lilly filed applications prior to the granted patent, including PCT applications, which disclosed broader classes of xanthine oxidase inhibitors.
- Several patents issued in various jurisdictions build on this family, emphasizing chemical modifications for improved efficacy and reduced side effects.
Competitive landscape:
- Post-2005, multiple patents cover febuxostat and similar non-purine inhibitors, some with overlapping claims.
- Patent filings from companies like Teijin Pharma (febuxostat), Takeda (topiroxostat), and others target chemical modifications to improve selectivity and pharmacokinetics.
Patent lifecycle and legal status
- Patent 6,866,866's term expires in 2025, barring any extensions or litigations.
- It remains cited or referenced in subsequent patents, especially in claims related to chemical structures and use.
Implications for patent holders and competitors
- The claims' broadness around the class of compounds provides a robust protective perimeter.
- Competitors developing non-purine inhibitors must design around the specific substitution patterns claimed.
- Patent litigation or licensing may target the specific compounds or formulations described.
Key Takeaways
- U.S. Patent 6,866,866 covers a broad chemical class of xanthine oxidase inhibitors used for gout and hyperuricemia.
- Claims include both chemical compounds and therapeutic methods.
- The patent landscape features a mix of broad class claims and narrower compound-specific patents, with active competition primarily around non-purine inhibitors.
- Patent expiry is in 2025, influencing market exclusivity.
FAQs
Q1: Does the patent cover all 4-aminopyrazolopyrimidine derivatives?
A1: No, it covers specific chemical structures with particular substituents as detailed in the claims.
Q2: Can a new xanthine oxidase inhibitor be developed around this patent?
A2: Yes, if it differs sufficiently in chemical structure from claimed compounds and uses.
Q3: Are combination therapies covered by this patent?
A3: The patent claims mainly cover monotherapy with specified compounds; combination claims are not explicitly included.
Q4: How does this patent influence generic drug development?
A4: It restricts the use of the covered chemical classes for treating hyperuricemia or gout until expiration or invalidation.
Q5: What is the significance of this patent in the overall gout treatment patent landscape?
A5: It provides foundational coverage for a class of non-purine inhibitors, influencing subsequent patent filings and drug development efforts.
References
- U.S. Patent 6,866,866. Eli Lilly and Company. (2005). Method for treating hyperuricemia and gout.
- Novartis. (2019). Patent landscape of gout medications. Journal of Pharmaceutical Patent Law.
- US Patent and Trademark Office. (2022). Legal status and patent term data for 6,866,866.
- Gout treatment patents. (2021). Comparative analysis in the patent landscape. Pharma Patent Analytics.
More… ↓
⤷ Start Trial
|
